Skip to main content
. 2021 May 6;22(9):4943. doi: 10.3390/ijms22094943

Figure 3.

Figure 3

Human vaccines and monoclonal antibodies (mAbs) used to fight E. coli infections. The candidate section describes the trademarks and the specific targeted antigens. Pre-clinical as well as each clinical phase are represented. Arrows reaching dotted line indicate a completed study for that phase, conversely, studies are ongoing.